Bio-Techne Corp (TECH) has had a spate of key developments, including the shipping of its next-generation, high-throughput
Leo Simple Western System. The Leo System paves the way for faster protein analysis. There are mixed opinions on TECH stocks, but some suggest potential for rise following the Leo System announcement. Q1 and Q2 FY2025 revenues surpassed estimates, displaying strong growth due in part to strategic moves. The firm has expanded its R&D Systems AI-Engineered Designer Protein Portfolio and RNAscope probes for advancing spatial biology. However, it also noted the enduring loss of 37% from investing in the stock three years ago. Prominent among its strategic partnerships are agreements with Leader Life Sciences, MedsanTek, Waters Corporation, and Oxford Nanopore Technologies. Simultaneously, the CEO sold $1.04mn worth of stocks.
Bio-Techne also faces legal challenges, a recent one being a reverse engineering claim against Miltenyi Biotec. Lastly, the firm declared its Q2 FY 2025 earnings call for February 5, expecting to provide key financial updates.
Bio-Techne Corp TECH News Analytics from Mon, 08 Apr 2024 07:00:00 GMT to Wed, 12 Mar 2025 10:59:00 GMT -
Rating 6
- Innovation 8
- Information 9
- Rumor -3
